PDL BioPharma Financial Ratios

PDL BioPharma Inc -- USA Stock  

USD 2.79  0.04  1.45%

We recommend you to use analysis of PDL BioPharma Inc fundamentals to see if markets are today mispricing the firm. We found thirty-seven available financial ratios for PDL BioPharma Inc which can be compared to its competitors. To make sure the equity is not overpriced, please check all PDL BioPharma Inc fundamentals including its Price to Book, Total Debt, Number of Employees, as well as the relationship between EBITDA and Cash Flow from Operations . Please also confirm PDL BioPharma Inc Price to Earning to check out the company can sustain itself for few more years.Use PDL BioPharma to enhance returns of your portfolios. The stock experiences large bullish trend. Check odds of PDL BioPharma to be traded at $3.07 in 30 days

PDL BioPharma Inc Valuation Over Time

Enterprise Value

PDL BioPharma Company Summary

PDL BioPharma competes with NantKwest, Del Mar, Dimension Therapeutics, Denali Therapeutics, and VBI Vaccines. PDL BioPharma Inc is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies methods for humanizing antibodies polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies. PDL BioPharma Inc. has license agreements with various biotechnology and pharmaceutical companies as well as acquires royalty and other assets. PDL BioPharma Inc was formerly known as Protein Design Labs Inc. and changed its name to PDL BioPharma Inc. in 2006. PDL BioPharma Inc. was founded in 1986 and is headquartered in Incline Village Nevada.

PDL BioPharma Cash Flow from Operations vs Current Ratio

PDL BioPharma Inc is considered to be number one stock in cash flow from operations category among related companies. It is rated below average in current ratio category among related companies . The ratio of Cash Flow from Operations to Current Ratio for PDL BioPharma Inc is about  23,329,114 

PDL BioPharma Inc Systematic Risk

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on PDL BioPharma Inc correlated with the market. If Beta is less then 0 PDL BioPharma generally moves in the opposite direction as compared to the market. If PDL BioPharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PDL BioPharma Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PDL BioPharma is generally in the same direction as the market. If Beta > 1 PDL BioPharma moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
< 46% 

Chance of Financial Distress

PDL BioPharma Inc has less than 46 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
PDL BioPharma is an interesting company.? They really do not make anything.? Instead, the finance patents within the pharma industry, providing financial monetization ... continue


PDL BioPharma Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth


Compare PDL BioPharma To Peers
John McLaughlin President CEO, Director
Dominique Monnet President, MBA
More Executives

Opportunity Range

January 20, 2018 Opportunity Range